Navigation Links
VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
Date:9/13/2007

SOUTH SAN FRANCISCO, Calif., Sept. 13 /PRNewswire-FirstCall/ -- VaxGen Inc. (Pink Sheets: VXGN) today announced further cost-cutting measures consistent with its continuing commitment to align its cost structure with its pursuit of strategic initiatives.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

VaxGen is reducing its workforce from 61 to 27 employees, which the company expects will lower its monthly cash expenditures used in operating activities to $1.4 million. The company will incur a restructuring charge of approximately $1.1 million in connection with this action. The terminations include executive officer Lance Ignon, Vice President of Corporate Affairs.

This is VaxGen's third restructuring since the U.S. Department of Health and Human Services (HHS) cancelled the company's contract to provide a modern anthrax vaccine for civilian biodefense in December 2006.

"Throughout this year we have retained only those resources that management felt could build value for our shareholders, either because they enhanced our ability to complete a strategic transaction or they were required to meet essential business objectives," said James P. Panek, VaxGen's President and CEO. "Based on our understanding of the nature and structure of such potential transactions, we are now able to take this further restructuring action. We remain optimistic about completing a strategic transaction and are in various stages of discussions with a variety of companies."

VaxGen has retained key resources necessary to support its pursuit of strategic transactions, including key scientific personnel for technical due diligence. The company has also retained people associated with the company's financial reporting obligations to the Securities and Exchange Commission. "These are not easy decisions, especially when you are talking about letting go of many talented and dedicated employees," Mr. Panek said. "In particular, Lance Ignon has tirelessly and competently fulfilled a variety of responsibilities during his more than seven years of service to VaxGen. Nonetheless, these staffing decisions are appropriate given the opportunities we are pursuing and the obligation we have to our shareholders."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the company's ability to reduce monthly cash expenditures used in operating activities and the possibility of selling or merging the company's remaining assets. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. A Further Step in Understanding Apoptosis Direct Detection of PARP Cleavage
2. OpGen recruits CEO to further gene-mapping business
3. Better collaboration urged to further Wisconsin biotech
4. Johnson Controls jumping further into hybrid-vehicle battery world
5. Preserve Samples for RNA Expression Microarrays RNAlater Around the World
6. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
7. Genomic DNA Preparation from RNAlater Preserved Tissues
8. QBIs PreserveX product passes initial test
9. Technology and mergers: Getting the strategic applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which is ... polymer exhibits properties to gently absorb compressive forces and return to its natural ...
(Date:3/23/2017)... 2017  SeraCare Life Sciences, Inc., a manufacturer ... diagnostics manufacturers and clinical laboratories, is announcing ... Inherited Cancer reference material for ... sequencing (NGS). The Seraseq™ Inherited Cancer DNA Mix ... industry experts to validate the ability of ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... In today,s pre-market research, Stock-Callers.com ... Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals ... and Regulus Therapeutics Inc. (NASDAQ: RGLS ). ... its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more ... ...
Breaking Biology Technology:
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
Breaking Biology News(10 mins):